Dr. Jorge Castillo is a global specialist in Waldenström Macroglobulinemia (WM) and Clinical Director of the Bing Center for WM at Dana-Farber Cancer Institute/Harvard Medical School. He captured the strong attention of WMers and caregivers from across the country as the presenter at a Waldenström breakout session during the Annual North American Educational Forum hosted by the Lymphoma Research Foundation (LRF) in Brooklyn, New York October 20-22, 2017. LRF is the largest organization in the country dedicated to eradicating the 70 Lymphoma sub-types that it represents. It has been committed to Waldenström education, our rare disease, for many years.
Dr. Castillo, Assistant Professor of Medicine at Harvard Medical School, is a masterful educator and gave a powerful, state-of-the-art presentation on “Treatment Options in Waldenström Macroglobulinemia” to WM patients. Arming patients with knowledge about WM is one of the most significant contributions Dr. Castillo can make in empowering us to become our own best health advocates. He discussed diagnostic criteria, manifestations of Waldenström, NCCN guidelines for the initiation of therapy, and several treatment options including ibrutinib, bendamustine, bortezomib and rituximab.